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540 | Med. Chem. Commun., 2014, 5,Machine-assisted synthesis of modulators of the
histone reader BRD9 using ﬂow methods of
chemistry and frontal aﬃnity chromatography†
Lucie Guetzoyan,a Richard J. Ingham,a Nikzad Nikbin,a Julien Rossignol,a
Michael Wolling,a Mark Baumert,b Nicola A. Burgess-Brown,c Claire M. Strain-
Damerell,c Leela Shrestha,c Paul E. Brennan,c Oleg Fedorov,c Stefan Knappc
and Steven V. Ley*a
A combination of conventional organic synthesis, remotely monitored ﬂow synthesis and bioassay
platforms, were used for the evaluation of novel inhibitors targeting bromodomains outside the well-
studied bromodomain and extra terminal (BET) family, here exempliﬁed by activity measurements on the
bromodomain of BRD9 protein, a component of some tissue-speciﬁc SWi/SNF chromatin remodelling
complexes. The Frontal Aﬃnity Chromatography combined with Mass Spectrometry (FAC-MS) method
proved to be reliable and results correlated well with an independent thermal shift assay.The process of drug discovery involves an iterative cycle of
design-synthesis-evaluation steps. The information obtained
from each cycle is then fed back to the design step, and the loop
is repeated until a suitable candidate emerges. Although this
approach has largely proven to be successful, drug discovery
still relies heavily on exhaustive screening protocols involving
the synthesis of a large number of molecules in order to map
out the most diverse chemical space relevant to the biological
target. Many obstacles must be overcome to achieve an ideal
guided discovery process, in which every molecule that is
produced takes the researcher one step closer to the desired
ligand. For example, the synthesis of a complex molecule
requiring multiple steps is still time consuming, labour inten-
sive and expensive. However, with the assistance of automation
and other enabling technologies, chemists can provide target
molecules rapidly. Nevertheless there is still oen a discon-
nection with the biological assessment of these molecules
creating a bottleneck in the process. There is dearth therefore in
the methods that can sensibly guide chemists to the next
compound in the discovery cycle.
One approach to achieve this “closed-loop” process is to
develop an integrated system which encompasses each step ofof Chemistry, University of Cambridge,
00@cam.ac.uk
rgh Way, Harlow, Essex, CM20 2NQ, UK
t Discovery Institute, Nuﬃeld Department
search Building, Roosevelt Drive, Oxford,
(ESI) available: Synthetic procedures,
details of the set-up for frontal aﬃnity
ta against 9 bromodomains. See DOI:
540–546the design, synthesis and functional evaluation elements of
drug discovery. For example, we1 and others2 have been inves-
tigating an integrated platform capable of performing chemical
synthesis and subsequent linked biological evaluation. For this,
we have reported the use of Frontal Aﬃnity Chromatography
(FAC)3 as a fast analysis protocol suitable for incorporation into
our ow chemistry synthesis platform. In this new work, we
report the incorporation of a Compact Mass Spectrometer
(CMS) to facilitate the analysis, and then use a ow assisted
synthesis coupled to the FAC-MS assay for the discovery of BRD9
protein's bromodomain modulators.
The bromodomain is a module found in many proteins4
including transcriptional co-activators and proteins associated
with the remodelling of chromatin.5 This module primarily
recognises specic post-translational protein modications6
most notably the 3-N-acetylation of lysine residues at the
N-terminus of histones.7
There are now over 40 proteins containing one or several
bromodomains encoded in the human genome which have
been grouped into eight families based on their structural
similarity.8 While many bromodomain containing proteins
have been linked to disease development, the main eﬀort in
chemical biology has been dedicated to the bromodomain and
extra-terminal (BET) family, which has been identied as a
therapeutic target involved in inammation,9 cancer10 and
pathological cardiac hypertrophy.11
In 2005, fragments were designed to target the p300/CBP
associated factor bromodomain (PCAF BRD).12 More recently,
the potent and selective inhibitors (+)-JQ1 (ref. 13) and I-BET9
were identied; these compounds share a triazolodiazepine
scaﬀold and inhibit bromodomains from the BET familyThis journal is © The Royal Society of Chemistry 2014
Fig. 1 Structure of triazole containing bromodomains inhibitors: (a)
triazolodiazepines; (b) urea containing triazoles; (c) fused
triazolopyrazines.
Scheme 1 Synthesis of compounds 4 and 5 in the triﬂuoromethyl
series. Reagents and conditions: (i) hydrazine monohydrate, ethanol,
microwave heating, 100 C, 60 min, quant. yield; (ii) triﬂuoroacetic
acid, microwave heating, 110 C, 70 min, 85%; (iii) phenylboronic acid
or para-methoxyphenylboronic acid, Pd(PPh3)4 (3 mol%), sat. Na2CO3,
ethanol–toluene 3 : 1, microwave heating, 120 C, 120 min, 24–44%.
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View Article Online(Fig. 1a). Furthermore, the related urea containing triazoles
depicted in Fig. 1b have been patented as BET inhibitors.14,15
Finally, the recently disclosed fused triazoles presented in
Fig. 1c have been reported to inhibit the BET bromodomains as
well as other family members such as BRD9, CECR2 and
CREBBP.16,17 However, the biological role of some bromodo-
mains remains poorly understood and a large proportion of
them lack any selective inhibitors that could help unveil their
individual functions. Amongst these, the bromodomain-con-
taining protein 9 (BRD9) has been shown to be inhibited by
several BET inhibitors even though it does not belong to the
BET family,16,17 highlighting the low specicity of some of theseThis journal is © The Royal Society of Chemistry 2014inhibitors. However, BRD9's function remains elusive even
though its interaction with H4K12Ac, an acetylated histone
involved in gene regulatory regions, has been demonstrated.18
Furthermore, recent studies established up-regulation of BRD9
in hepatocellular carcinomas19 and its implication into SWi/
SNF complexes, complexes that are involved in numerous types
of cancers.20Chemistry
Bromosporine16 (Fig. 1c) was used as the starting point for the
design of a new series of molecules. Two triuoromethyl
analogues, as well as sulfonamide group elaboration of bro-
mosporine were developed to explore either enhanced binding
or improved selectivity towards BRD9's bromodomain.
The preparation of the triuoromethyl analogues is depicted
in Scheme 1. 3,6-Dichloropyrazine 1 was rst converted to its
mono hydrazine derivative 2 and subsequent ring closing with
triuoroacetic acid aﬀorded the triazolopyrazine scaﬀold 3.
Finally, a Suzuki coupling aﬀorded compounds 4 and 5 in
moderate yields using batch microwave chemistry.
The preparation of the second series of analogues based on
the amino triazolopyrazine core 9 proved to be more chal-
lenging and the application of new ow chemistry technologies
was considered as an alternative approach. We chose a Curtius
rearrangement as the most expeditious route for the conversion
of commercially-available 3,6-dichloropyridazine-4-carboxylic
acid 6 to amine intermediate 8 (Scheme 2). The Curtius rear-
rangement requires heating of stoichiometric quantities of
diphenyl phosphoryl azide (DPPA), a hazardous reagent, and
results in the release of a large volume of nitrogen gas upon
conversion to the product.
The advantages associated with performing large scale Cur-
tius rearrangement in ow had been demonstrated previously
by our group.21 The need for large quantities of compound 9 led
us to devise an automated synthesis approach for the prepara-
tion of the key building block 7 (Fig. 2). By using a ow reactor,
we could perform both the generation of the intermediate acyl
azide and the subsequent rearrangement in a continuousMed. Chem. Commun., 2014, 5, 540–546 | 541
Scheme 2 Synthesis of amino triazolopyrazine 9. Reagents and
conditions: (i) (ﬂow conditions) DPPA, t-BuOH, triethylamine,
toluene–acetonitrile 7 : 3, 120 C, 140 min, 39%; (ii) HCl (4 M in
dioxane), dichloromethane, quant.; (iii) hydrazine monohydrate, water,
microwave heating, 100 C, 3 h, 75%; (iv) glacial acetic acid, microwave
heating, 120 C, 5 h, 79%.
Fig. 2 Automated ﬂow set-up for large scale Curtius rearrangement
(40 mmol scale). A remote monitoring protocol allowed data from the
reactor and the balances to be combined into a single display, which
could be observed remotely over the internet.
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View Article Onlinesequence. This avoids any requirement to isolate large quanti-
ties of unstable acyl azide intermediate. Furthermore, only a
small amount of the DPPA reagent is heated at any one time,
allowing a large amount of material to be processed more safely
than the corresponding batch procedure.21,22 The use of an in-
line pressure regulator controls the gas produced during the
reaction.
A possible disadvantage associated with the ow method is
its serial nature which can lead to long processing times for
large scale operations. In this example, 40 mmol of product can
be processed over 22 hours. The use of remote monitoring
devices23 allows us to observe reaction parameters such as
temperature and pressure to ensure overall safety of the process.
Connected digital balances could also be monitored to conrm
accurate ow rates and consistent stoichiometric ratios over the
extended reaction time. The subsequent Boc protecting group
deprotection and triazole ring formation aﬀorded over 1 g of 9.
The required boronic ester partners 11–14 (Scheme 3) were
obtained from the commercially available boronic acid 10
which was rst converted to its corresponding pinacol ester and
then reacted with aryl sulfonyl chlorides to aﬀord intermediates
11–14.
The triazolopyridazine core 9 proved to be a challenging
partner for cross coupling reactions, possibly due to initial542 | Med. Chem. Commun., 2014, 5, 540–546poisoning of the palladium catalyst by the nitrogen-containing
heterocycles. Monodentate phosphine ligands for palladium,
such as electron rich and bulky 2-dicyclohexylphosphino-
20,40,60-triisopropylbiphenyl (XPhos), which is considered to be
an eﬀective ligand when dealing with heterocyclic substrates,
were found to be unstable under the reaction conditions and
signicant palladium black deposition was observed. Bidentate
phosphine ligands such as 1,10-bis(diphenylphosphino)ferro-
cene (dppf) proved to be more stable under the reaction
conditions, and extensive ligand screening identied the highly
electron-rich and bulky 1,10-bis(di-tert-butylphosphino)ferro-
cene (dtbpf) as the most promising ligand for palladium. This
coupling then proceeded with a reasonable conversion and
yield, and with selectivity for the heterocyclic chlorine target
(15–18). It is worth mentioning however that our attempts to
optimise the Suzuki coupling using an automated ow platform
were not fruitful. By their very nature, on a small scale, meso-
ow reactions oen employ more reagents and solvents than
corresponding batch processes.24 Furthermore, the sensitivity
of the reaction to oxygen and the low solubility of some of the
reagents makes the reaction challenging, and is therefore better
suited to batch processing using microwave irradiation.
Purication of the products by preparative HPLC furnished
sulfonamides 15–18. Based upon the structure of bromospor-
ine, attempts were made to convert the free amine groups to
their ethyl carbamate derivatives. Interestingly, the pendant
amine of the heterocyclic core seems to be strongly deactivated
following installation of the sulfonamide moiety, rendering its
further decoration very diﬃcult. As a result, only the analogues
19 and 20 were prepared, puried and evaluated as BRD9
binders (vide infra).Evaluation of binding aﬃnity for the
BRD9 bromodomain using FAC-MS
FAC is a biophysical method which requires the injection of
large plugs of analyte(s) into a column containing the immo-
bilised target of interest, hence reaching saturation of the target
(indicated by a plateau in ion count for every injection).
Consequently, we needed to rstly modify the FAC apparatus to
accommodate the small quantities of overexpressed BRD9
bromodomain. In order to achieve this, biotinylated BRD9
bromodomain was over-expressed and puried according to
previously published procedures.13 This target protein was then
immobilised on streptavidin coated beads which resulted in a
custom made column (15 mL column, Fig. 3a).
The packed column was validated by injecting bromosporine
and one other known binder16 (compound 21, Fig. 3b) at
diﬀerent concentrations (for details, see Experimental section),
giving access to the loading of functional BRD9 bromodomain,
which was determined to be approximately 2 nmol. Further-
more, in all cases (i.e. bromosporine and its analogue 21, both
in Phosphate Buﬀer Saline – PBS – and 100 mM ammonium
acetate), aﬃnity constants compared well with literature IC50
data,16 with the same order of magnitude and the same trend.
Non-specic interactions were ruled out by injecting a voidThis journal is © The Royal Society of Chemistry 2014
Scheme 3 Synthesis of compounds 15–20. Reagents and conditions: (i) pinacol, acetonitrile, 25 C, 18 h; (ii) aryl sulfonyl chloride, pyridine,
ethanol, 25 C, 18 h, 63–77% over two steps; (iii) triazolopyridazine core 9, potassium phosphate, [1,10-bis(di-tert-butylphosphino)ferrocene]
dichloro palladium(II), n-butanol–water 7 : 3, 1–35%; (iv) ethyl chloroformate, triethylamine, tetrahydrofuran, 25 C, 5 min, 95%.
Fig. 3 BRD9 immobilisation and assessment of the resulting column:
(a) commercially available (left, Kinesis) and custom made columns
(center and right); (b) structure of the bromosporine analogue 21 and
void marker 22.25
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View Article Onlinemarker (Fig. 3c) and bromosporine into a blank column; in
these conditions, bromosporine did not show any signicant
retention. The protein loading on the column implies that low
micromolar concentrations need to be accurately detected inFig. 4 Frontal aﬃnity chromatography assay. Direct estimation of aﬃnit
times of void marker 22 and synthesised compounds 4, 5, 9, 15, 16 and
This journal is © The Royal Society of Chemistry 2014order to provide reliable information. The system was further
coupled to a CMS, which provided better sensitivity than UV
detection (see ESI†), as well as detection of compounds that are
not UV active (such as the void marker 22). Although mass
spectroscopy is not compatible with non-volatile buﬀers such as
PBS, we were pleased to nd that the BRD9 bromodomain was
stable and functional in an ammonium acetate buﬀer. In order
to compare the aﬃnity of analogues 4, 5, and 15–20, they were
injected separately into the FAC-MS system which contained the
BRD9 bromodomain column. The results obtained for the
aﬃnity screen are shown in Fig. 4.
We have previously reported that the correlation between the
calculated aﬃnity of compounds for their target (as Kd deter-
mined by several injections at diﬀerent concentrations) and the
retention time measured on single injections (one injection at
one concentration),1 using the principles of frontal aﬃnity
chromatography.26 With single injections, we were able to rank
quickly the compounds under study. Gratifyingly, the samey towards the bromodomain of BRD9 protein by comparing retention
18–20 at the same concentration (4 mM).
Med. Chem. Commun., 2014, 5, 540–546 | 543
Table 1 Retention times calculated from FAC-MS assay and thermal
stabilisation of BRD9 bromodomain-containing protein
Compound Vretention
a (mL) BRD9b (DTm,obs)
Void 160 n/a
4 212 0.6
5 270 +0.6
15 784 +2.4
18 1167 +4.3
20 947 +2.7
Bromosporine >3600c +8.8
a Elution volume for which 50% of the ion count is attained. The
retention volume was determined using a custom-made Excel le.
b Diﬀerence in temperature of denaturation of the protein with and
without the ligand, data in C. c At a similar concentration (4 mM),
bromosporine did not elute during the 120 min run; it was gradually
eluted over a long period and no plateau was detected. An accurate
breakthrough volume can be calculated for bromosporine using a
more concentrated sample.
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View Article Onlinetrend was conrmed by a separate thermal shi assay (Table 1),
in accordance with a correlation previously reported between
thermal shi data and aﬃnity constants.13
The results showed that the BRD9 bromodomain column
was of appropriate dimensions for rapid screening purposes.
Furthermore, the diﬀerence of retention volumes obtained is
signicant enough to allow for the accurate distinction between
low to medium (typically hundreds of micromolar) aﬃnity
compounds, making this approach of potential value in frag-
ment-based drug discovery. Only 2 nmol of protein target
(i.e. around 35 mg of recombinant biotinylated BRD9 bromo-
domain) were suﬃcient to carry out assays.
During a period of six months, no obvious loss of binding
capacity for bromosporine was noticed (see Experimental
section). This means that unlike conventional bioassays, eval-
uating a larger collection of compounds does not require a
larger amount of protein which can be very benecial and
consequently may help overcome the disconnection between
chemistry and biology. Consistent data were achieved and
cross-validated by a widely used biophysical technique, namely
a thermal shi assay.
A thermal shi assay against eight other proteins that are
spread across the bromodomain phylogenetic tree8 was also
carried out (see ESI†). Compounds 4, 5 and 20 displayed no
noteworthy stabilisation of any of the bromodomains tested.
Compound 15 on the other hand showed a mild selectivity for
the rst BRD4 bromodomain, while the most potent compound
of the series, compound 18, exhibited stabilisation of both
BRD4 bromodomain and the transcription factor EP300, hence
did not display any selectivity for the BRD9 bromodomain.Conclusions
In conclusion, a combination of ow and microwave chemistry
methods quickly delivered eight analogues of bromosporine
that were subsequently evaluated for their aﬃnity for bromo-
domain proteins. In particular, the implementation of an
automated Curtius rearrangement reaction facilitated the544 | Med. Chem. Commun., 2014, 5, 540–546processing of a large amount of material in a safer manner than
the corresponding batch process. The remote monitoring of
this hazardous process ensured its safety. However, optimising
a challenging cross coupling step using this automated plat-
form was not successful; this is an area of ongoing research
within our and other groups.27 A simple, robust and reliable
screening method using frontal aﬃnity chromatography
coupled with mass spectrometry aﬀorded rapid binding infor-
mation towards the BRD9 bromodomain that was additionally
conrmed by a thermal shi assay.
Future work will include the preparation of an array of bro-
modomain containing columns to allow for rapid screening for
aﬃnity and selectivity. The development of more selective
inhibitors and the exploration in more detail of fragment-based
discovery of bromodomain modulators, both employing our
ow assisted synthesis capabilities combined with the FAC-MS
assay set-up, is on-going in our laboratory.Experimental section
Chemistry
Synthetic procedures and characterisation can be found in the
ESI.†Frontal aﬃnity chromatography
General considerations. Ammonium acetate was bought
from Breckland Scientic. Streptavidin coated polyacrylate
beads (Streptavidin Plus UltraLink Resin) were purchased from
Pierce. Phosphate buﬀer saline (PBS) and formic acid were
bought from Aldrich, HPLC grade methanol from Fischer
Scientic. 100 mM ammonium acetate buﬀer was prepared with
HPLC grade water (Rathburn) and was sterilised by ltration
(Millipore, 0.22 mM) prior to use. DMSO (Alfa Aesar) was used
without any further purication. The 15 mL guard column (1mm
 2 cm) was purchased from Kinesis. FAC assays were run on a
modied Agilent 1100 HPLC system with a 100 mL injection
syringe and 100 mM ammonium acetate was used as the eluent.
The temperature of the thermostatic oven was set at 20 C. An
Expression CMS single quadrupole mass spectrometer (Advion)
was connected via a T-piece to the HPLC output and to a pump
which delivered solution of 0.1% formic acid in methanol
(make-up buﬀer). Stock solutions of compounds were prepared
at a concentration of 50 mM in DMSO and stored at 20 C.
Methods. The HPLC system was set to inject 600 mL of 4 mM
of analyte at 30 mLmin1 for 120min. Themake-up buﬀer (0.1%
formic acid in methanol) pump was set at a ow rate of 200 mL
min1. Two wavelengths were simultaneously monitored at
220 nm (DMSO) and 254 nm (analyte) using a Diode Array UV
Detector, and the mass detection on the Expression CMS was
used in positive mode with Selective Ion Mode (SIM, span 1,
dwell time 500 ms).
Preparation and assessment of the BRD9 bromodomain
column. The 15 mL column was packed with streptavidin beads,
installed onto the HPLC stack and washed for 30 min at 50 mL
min1 with PBS buﬀer. 100 mL of a solution of biotinylated
bromodomain of BRD9 protein in PBS, which wasThis journal is © The Royal Society of Chemistry 2014
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View Article Onlineoverexpressed according to previously published procedures,13
was then injected three times through the column, at a ow rate
of 50 mL min1. The column was subsequently evaluated with
bromosporine. In practice, from a 50 mM stock solution of
bromosporine in DMSO were prepared solutions at concentra-
tions of 15, 7.5, 3.75, and 1.875 mM, both in PBS and in 100 mM
ammonium acetate buﬀer. Each of these solutions was then
infused in duplicate following the HPLC method described in
the previous section, and the amount of active loaded protein
(Bt) and aﬃnity constant (Kd) values calculated as explained
previously.1 In these conditions, Kd and Bt were respectively
found to be 1.48  0.42 mM and 2.07  0.23 nmol, satisfyingly
both in PBS and in 100 mM ammonium acetate buﬀer. The
samemethod was employed with the analogue of bromosporine
21 and gave similar Bt and a Kd of 8.35  1.25 mM. In order to
show the reproducibility of this assay, the same experiment was
performed aer six months on the same column, and no change
in Kd or Bt was detected within experimental error. Additionally,
during the six-month period in which the column was used
recurrently, the breakthrough volume for a 50 mM sample of
bromosporine was found to be constant at 324  8 mL, vali-
dating the stability of the immobilised bromodomain protein
on the column as well as the reproducibility of the technique.
When not in use, the column was stored at 4 C in a buﬀer
solution (either PBS or 100 mM ammonium acetate) containing
0.1% sodium azide.Thermal shi assay
Thermal melting experiments were carried out using a Mx3005p
Real Time PCR machine (Stratagene) as previously described.28Acknowledgements
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